RecruitMe

Immune Reconstitution and Long-Term Immunologic Changes Following Transitionfrom anti-CD20 Therapy

Study of OCR/RTX vs. Diroximel for Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) or Clinically Isolated Syndrome (CIS)

Sponsor:	Biogen
Enrolling:	Male and Female Patients
IRB Number:	AAAU2756
Contact:	Kaho Onomichi: 212-305-2434 / mscenter_neuro@cumc.columbia.edu

Additional Study Information: The purpose of this study is to evaluate the differences between immune profiles of individuals remaining on Ocrelizumab/Rituximab versus those transitioning to diroximel fumarate at two years. Baseline visits for subjects transitioning to diroximel fumarate (DRF) will take place 6 months after last Ocrelizumab (OCR) or Rituximab (RTX) dose, prior to beginning DRF. Baseline visit for individuals remaining on OCR/RTX will take place prior to OCR/RTX dose. Visits will occur every 6 months for 24 months (total of 5 study visits) with optional extension visits also occurring every 6 months for an additional 12 months (total of 2 visits). Visits will include blood draw as well as clinical assessments.

Investigator

Rebecca Straus Farber, MD

See all studies by this doctor

Do You Qualify?

Are you between the ages of 18-60?	Yes	No
Have you been diagnosed with Relapsing-Remitting Multiple Sclerosis (RRMS) or Clinically Isolated Syndrome (CIS)?	Yes	No
Have you been on Ocrelizumab/Ocrevus (OCR) or Rituximab/Rituxan (RTX) for at least 2 years?	Yes	No

Submit

Cancel

You may be eligible for this study

Place Holder

I would like to receive email alerts about studies like this. (Optional)

Required: I agree to the terms of use

CAPTCHA

What code is in the image?

Enter the characters shown in the image.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel

For more information, please contact:

Kaho Onomichi
mscenter_neuro@cumc.columbia.edu
212-305-2434

This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.

I AGREE